X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Procter & Gamble Health with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs CIPLA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH CIPLA PROCTER & GAMBLE HEALTH/
CIPLA
 
P/E (TTM) x 51.4 24.5 209.2% View Chart
P/BV x 4.6 2.6 175.7% View Chart
Dividend Yield % 10.2 0.6 1,591.8%  

Financials

 PROCTER & GAMBLE HEALTH   CIPLA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
CIPLA
Mar-18
PROCTER & GAMBLE HEALTH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs3,549663 535.3%   
Low Rs1,301479 271.7%   
Sales per share (Unadj.) Rs511.4189.0 270.6%  
Earnings per share (Unadj.) Rs61.317.6 348.3%  
Cash flow per share (Unadj.) Rs74.034.0 217.5%  
Dividends per share (Unadj.) Rs440.003.00 14,666.7%  
Dividend yield (eoy) %18.10.5 3,453.3%  
Book value per share (Unadj.) Rs927.8176.7 525.0%  
Shares outstanding (eoy) m16.60805.12 2.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.73.0 157.0%   
Avg P/E ratio x39.632.5 121.9%  
P/CF ratio (eoy) x32.816.8 195.3%  
Price / Book Value ratio x2.63.2 80.9%  
Dividend payout %717.917.1 4,210.4%   
Avg Mkt Cap Rs m40,257459,724 8.8%   
No. of employees `0001.123.6 4.8%   
Total wages/salary Rs m1,31326,901 4.9%   
Avg. sales/employee Rs Th7,486.76,446.1 116.1%   
Avg. wages/employee Rs Th1,157.61,139.4 101.6%   
Avg. net profit/employee Rs Th897.2600.0 149.5%   
INCOME DATA
Net Sales Rs m8,490152,193 5.6%  
Other income Rs m2443,577 6.8%   
Total revenues Rs m8,734155,769 5.6%   
Gross profit Rs m1,48228,264 5.2%  
Depreciation Rs m21113,228 1.6%   
Interest Rs m01,142 0.0%   
Profit before tax Rs m1,51417,470 8.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m66-775 -8.5%   
Tax Rs m5632,501 22.5%   
Profit after tax Rs m1,01714,166 7.2%  
Gross profit margin %17.518.6 94.0%  
Effective tax rate %37.114.3 259.5%   
Net profit margin %12.09.3 128.7%  
BALANCE SHEET DATA
Current assets Rs m15,343108,141 14.2%   
Current liabilities Rs m1,96038,322 5.1%   
Net working cap to sales %157.645.9 343.6%  
Current ratio x7.82.8 277.4%  
Inventory Days Days4997 50.2%  
Debtors Days Days2874 38.2%  
Net fixed assets Rs m1,209109,411 1.1%   
Share capital Rs m1661,610 10.3%   
"Free" reserves Rs m15,235140,682 10.8%   
Net worth Rs m15,401142,292 10.8%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m17,595228,606 7.7%  
Interest coverage xNM16.3-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.7 72.5%   
Return on assets %5.86.7 86.4%  
Return on equity %6.610.0 66.4%  
Return on capital %10.310.0 103.1%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63651,691 3.2%   
Fx outflow Rs m4,36821,033 20.8%   
Net fx Rs m-2,73230,658 -8.9%   
CASH FLOW
From Operations Rs m-1,30414,628 -8.9%  
From Investments Rs m12,697-8,540 -148.7%  
From Financial Activity Rs m-301-3,855 7.8%  
Net Cashflow Rs m11,0932,431 456.3%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 51.8 20.8 249.0%  
Indian inst/Mut Fund % 18.2 12.2 149.2%  
FIIs % 1.0 23.7 4.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 29.1 26.2 111.1%  
Shareholders   28,591 161,166 17.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   SUVEN LIFESCIENCES  SHASUN PHARMA  NOVARTIS  TTK HEALTHCARE  SUN PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 267 Points Lower; Metal and Capital Goods Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Aug 21, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - AUROBINDO PHARMA COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS